InsidersTradesSigma
Follow the PMV Pharmaceuticals, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, PMV Pharmaceuticals, Inc. has published 78 public disclosures. Market capitalisation: €69.6m. The latest transaction was reported on 29 October 2025 (Levée d'options). Among the most active insiders: Schroeder Thilo. The full history is accessible without an account.
78
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€17m
43 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate PMV Pharmaceuticals, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$4.00.
45Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 29 October 2025
Declarations78 total
220,643 shares@ US$1.3747.0% of flowCommon StockSEC:0001341642-25-000004:0
1,000,000 shares@ US$1.5213.4% of flowCommon StockSEC:0000947871-25-000927:0
500,000 shares@ US$1.809.1% of flowCommon StockSEC:0000947871-25-000854:0
23,151 shares@ US$1.0648100.0% of flowCommon StockSEC:0001415889-25-019386:0
33,065 shares@ US$1.064540.3% of flowCommon StockSEC:0001415889-25-019384:0
28,249 shares@ US$1.064786.6% of flowCommon StockSEC:0001415889-25-019382:0
58,411 shares@ US$1.064518.0% of flowCommon StockSEC:0001415889-25-019380:0
91,750 shares@ US$0.5318.5% of flowCommon StockSEC:0001415889-25-001853:0
7,218 shares@ US$1.503618.6% of flowCommon StockSEC:0001415889-24-023313:0
2,891 shares@ US$1.5036100.0% of flowCommon StockSEC:0001415889-24-023309:0
163,890 shares0Common StockSEC:0001209191-24-001993:0
82,220 shares0Common StockSEC:0001209191-24-001995:0
95,555 shares0Common StockSEC:0001209191-24-001999:0
87,786 shares@ US$2.232.3% of flowCommon StockSEC:0000947871-23-001104:0
198,407 shares@ US$0.5339.8% of flowCommon StockSEC:0001209191-23-054997:0
6,291 shares@ US$6.6223.0% of flowCommon StockSEC:0001209191-23-049751:0
4,104 shares@ US$6.6259.4% of flowCommon StockSEC:0001209191-23-049759:0
85,500 shares@ US$0.5316.4% of flowCommon StockSEC:0001209191-23-045010:0
2,560 shares0Common StockSEC:0001209191-23-005476:0
52,200 shares0Common StockSEC:0001209191-22-049692:0
34,050 shares0Common StockSEC:0001209191-22-049694:0
26,253 shares@ US$15.930.57% mcap5.2% of flowCommon StockSEC:0000947871-22-000675:0
33,000 shares@ US$0.530.024% mcap26.2% of flowCommon StockSEC:0001209191-22-026341:0
4,000 shares@ US$3.220.017% mcap8.7% of flowCommon StockSEC:0001209191-22-025171:0
365,000 shares@ US$21.5210.29% mcap94.8% of flowCommon StockSEC:0000947871-22-000429:0
25 of 78 declarations
关于 PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc.（股票代码：PMVP）是一家在美国纳斯达克市场上市的美国生物技术公司，专注于精准肿瘤学。该公司正在开发小分子疗法，旨在靶向 p53 突变，这是癌症生物学中最重要的肿瘤抑制途径之一。其核心科学论点是恢复突变 p53 的功能，从而重新激活身体的天然抗癌机制。PMV Pharmaceuticals 由 David Mack 博士、Arnold Levine 博士和 Thomas Shenk 博士于2013年创立，总部位于新泽西州普林斯顿。([pmvpharma.com](https://www.pmvpharma.com/?utm_source=openai)) 该公司的主要临床项目是 rezatapopt，一种旨在治疗携带 TP53 Y220C 突变的肿瘤的候选药物。PMV Pharma 的开发策略围绕着肿瘤无关的方法：该药物旨在治疗由基因改变而非器官来源定义的癌症。在最近的披露中，管理层表示预计将在2027年第一季度提交 rezatapopt 用于铂耐药/难治性卵巢癌的新药申请（NDA），这使得该资产处于高级但仍处于商业化前阶段。最近的临床和科学里程碑，包括 Phase 2 PYNNACLE 中期数据和《新英格兰医学杂志》上发表的描述首次人体数据，增强了公司的可信度，并有助于验证其 p53 平台背后的科学依据。([ir.pmvpharma.com](https://ir.pmvpharma.com/news-releases/news-release-details/pmv-pharmaceuticals-reports-full-year-2025-financial-results-and/?utm_source=openai)) 从竞争角度来看，PMV Pharmaceuticals 占据了一个高度专业的利基市场。其差异化在于靶向突变 p53（一个历史上难以攻克的药物靶点），以及专注于具有高度未满足医疗需求的明确分子亚群患者。这种专注如果临床和监管执行保持积极，可能会带来巨大的上行空间，但这也意味着投资案例集中在少数几个项目上，因此对试验结果、监管时机和融资需求敏感。最近的全年和季度更新表明，PMV 仍然是一家临床阶段生物技术公司，资本配置和管线进展集中在 rezatapopt 和更广泛的 p53 平台上。([ir.pmvpharma.com](https://ir.pmvpharma.com/news-releases/news-release-details/pmv-pharmaceuticals-reports-full-year-2025-financial-results-and/?utm_source=openai)) 从地理上看，PMV 主要在美国运营，其公司和研发活动集中在新泽西州普林斯顿。该公司最近还宣布了董事会主席的过渡，这突显了其在推进关键临床和监管里程碑方面的积极治理阶段。对于寻求投资美国纳斯达克上市生物技术公司的欧洲投资者而言，PMVP 是一个高风险、高潜力的精准肿瘤学案例：科学上具有差异化，仍依赖于执行，并与 rezatapopt 开发和最终监管备案的结果密切相关。([ir.pmvpharma.com](https://ir.pmvpharma.com/news-releases/news-release-details/pmv-pharmaceuticals-announces-board-chair-transition/?utm_source=openai))
